| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2023―May―18 |
Development of subunit vaccines against severe acute respiratory syndrome |
L. Du, Y. He, S. Jiang, B.-J. Zheng |
| 2 |
[GO] |
2023―Feb―27 |
Anakinra as a potential treatment for COVID-19 |
|
| 3 |
[GO] |
2022―Dec―16 |
COVID-19 vaccination in patients with multiple sclerosis receiving disease-modifying therapies: pragmatic issues |
I.-A. Chirap-Mitulschi, C. Ghimus, A.R. Chirap-Mitulschi, S.A. Antoniu, R. Dragomir |
| 4 |
[GO] |
2022―Dec―16 |
New product intros [deucravacitinib (first-in-class); eflapegrastim; ensitrelvir; monovalent, recombinant-protein next-generation COVID-19 vaccine, adjuvanted using GSK's pandemic adjuvant; tozinameran/famtozinameran] |
|
| 5 |
[GO] |
2022―Nov―09 |
New product intros (finasteride/tadalafil (new combination); sutimlimab; human SARS-CoV-2 recombinant nanoparticle vaccine, adjuvanted with AS03; bupropion hydrochloride/dextromethorphan hydrobromide (new combination)) |
|
| 6 |
[GO] |
2022―Jul―08 |
Molnupiravir for the treatment of COVID-19 |
B.G. Santani, B.W. LeBlanc, R.P. Thakare |
| 7 |
[GO] |
2022―May―06 |
Fluticasone propionate as a potential treatment for COVID-19 |
M.W. McCarthy |
| 8 |
[GO] |
2022―May―06 |
New product intros [ansuvimab; benzoyl peroxide/tretinoin (new combination); faricimab; gallium (68Ga) gozetotide, kit for preparation; leuprolide mesylate; lutetium (177Lu) vipivotide tetraxetan; SARS-CoV-2 recombinant spike protein nanoparticle vaccine] |
|
| 9 |
[GO] |
2021―Apr―07 |
New product intros [Ad5-nCoV, COVID-19 inactivated vaccine (WIV04 strain), Ebola virus vaccine (rVSV-EBOV, live), JNJ-78436735, lonafarnib, margetuximab, romiplostim (new indication), tenapanor (first-in-class), tirbanibulin, tocilizumab (new indication), trilaciclib hydrochloride, ZF-2001] |
A. Babu |
| 10 |
[GO] |
2021―Mar―05 |
New product intros [berotralstat hydrochloride, cetuximab sarotalocan, daratumumab sc (new indication), eptacog beta, coagulation factor VIIa-jncw, etesevimab, evinacumab-dgnb (first-in-class), human SARS-CoV-2 inactivated vaccine, inclisiran, orelabrutinib, relugolix (new indication), remogliflozin etabonate/vildagliptin (new combination), surufatinib, voclosporin] |
|
| 11 |
[GO] |
2021―Feb―15 |
New product intros [anakinra (new indication), bamlanivimab, baricitinib (new indication), BBIBP-CorV, belimumab (new indication), calcium oxybate/magnesium oxybate/potassium oxybate/sodium oxybate (new formulation), casirivimab/imdevimab, ensartinib hydrochloride, favipiravir (new indication), Gam-COVID-Vac, inactivated SARS-CoV-2 vaccine, loteprednol etabonate (new indication), lumasiran (first-in-class), mRNA-1273, rilonacept (new indication), tozinameran] |
|
|
